0.18 USD
▲+0.00+4.55%
盘后 0.17 -1.50%
2026-08-03
市值
$88.73M
市盈率
—
EPS
-0.78
股息率
—
52 周区间
0.11 – 3.87
成交量
14.76M
Beta
2.04
目标价
3.86
52W 低 0.1152W 高 3.87
价格走势
公司简介
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp...